JP7404226B2 - 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス - Google Patents

向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス Download PDF

Info

Publication number
JP7404226B2
JP7404226B2 JP2020502265A JP2020502265A JP7404226B2 JP 7404226 B2 JP7404226 B2 JP 7404226B2 JP 2020502265 A JP2020502265 A JP 2020502265A JP 2020502265 A JP2020502265 A JP 2020502265A JP 7404226 B2 JP7404226 B2 JP 7404226B2
Authority
JP
Japan
Prior art keywords
per
amount
antigen
type
hib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527571A (ja
JP2020527571A5 (enExample
Inventor
ラケシュ クマール
ジット シャルマ インダー
ブヤンカトラオ シトール アニル
ドッダパーネニ マノハール
ジョーティ シャルマ ヒット
Original Assignee
セラム インスティテュート オブ インディア プライベート リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラム インスティテュート オブ インディア プライベート リミティド filed Critical セラム インスティテュート オブ インディア プライベート リミティド
Publication of JP2020527571A publication Critical patent/JP2020527571A/ja
Publication of JP2020527571A5 publication Critical patent/JP2020527571A5/ja
Application granted granted Critical
Publication of JP7404226B2 publication Critical patent/JP7404226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020502265A 2017-07-18 2018-07-13 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス Active JP7404226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721025513 2017-07-18
IN201721025513 2017-07-18
PCT/IB2018/055180 WO2019016654A1 (en) 2017-07-18 2018-07-13 IMMUNOGENIC COMPOSITION WITH IMPROVED STABILITY, ENHANCED IMMUNOGENICITY, AND LESS REACTOGENICITY, AND PREPARATION METHOD THEREOF

Publications (3)

Publication Number Publication Date
JP2020527571A JP2020527571A (ja) 2020-09-10
JP2020527571A5 JP2020527571A5 (enExample) 2021-08-19
JP7404226B2 true JP7404226B2 (ja) 2023-12-25

Family

ID=63556364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502265A Active JP7404226B2 (ja) 2017-07-18 2018-07-13 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス

Country Status (21)

Country Link
US (1) US11179453B2 (enExample)
EP (1) EP3655024A1 (enExample)
JP (1) JP7404226B2 (enExample)
KR (1) KR102657910B1 (enExample)
CN (1) CN111032078A (enExample)
AU (1) AU2018302767B2 (enExample)
BR (1) BR112020000999A2 (enExample)
CA (1) CA3070039A1 (enExample)
CO (1) CO2020001765A2 (enExample)
EA (1) EA202090316A1 (enExample)
GE (1) GEP20227386B (enExample)
JO (1) JOP20180069B1 (enExample)
MX (1) MX2020000441A (enExample)
PE (1) PE20201443A1 (enExample)
PH (1) PH12020500133A1 (enExample)
SG (1) SG11202000224SA (enExample)
TW (1) TWI786153B (enExample)
UA (1) UA128204C2 (enExample)
UY (1) UY37811A (enExample)
WO (1) WO2019016654A1 (enExample)
ZA (1) ZA202000889B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AU2007224734C1 (en) 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
EP3697439A1 (en) * 2017-10-18 2020-08-26 Institut Pasteur de Lille Bordetella strains expressing serotype 3 fimbriae
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP3988290A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method for manufacturing a spectacle lens
EP3988288A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
EP3988289A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법
MY208608A (en) * 2021-04-20 2025-05-20 Km Biologics Co Ltd Liquid sextuple vaccine composition
CN120826235A (zh) * 2023-03-16 2025-10-21 艾芬尼维克斯公司 免疫原性组合物
CN119799602A (zh) * 2025-03-17 2025-04-11 艾美坚持生物制药有限公司 一种破伤风梭状芽胞杆菌发酵培养基及培养方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020322A2 (en) 2006-08-15 2008-02-21 Novatris Ag Combination vaccines with 1-hydroxy-2-phenoxyethane preservative
JP2008120833A (ja) 1995-06-23 2008-05-29 Glaxosmithkline Biologicals Sa リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物
JP2012506420A (ja) 2008-10-24 2012-03-15 パナセア バイオテック リミテッド 全細胞百日咳を含む混合ワクチン
JP2012506421A (ja) 2008-10-24 2012-03-15 パナセア バイオテック リミテッド 新規な無細胞百日咳ワクチン組成物およびその製造方法
WO2012093406A2 (en) 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000016I1 (de) 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
BR9714980A (pt) 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
JP6564367B2 (ja) * 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
BR112018005291A2 (pt) * 2015-09-16 2018-10-09 Lg Chemical Ltd composição para vacina combinada para dosagem múltipla

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008120833A (ja) 1995-06-23 2008-05-29 Glaxosmithkline Biologicals Sa リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物
WO2008020322A2 (en) 2006-08-15 2008-02-21 Novatris Ag Combination vaccines with 1-hydroxy-2-phenoxyethane preservative
JP2012506420A (ja) 2008-10-24 2012-03-15 パナセア バイオテック リミテッド 全細胞百日咳を含む混合ワクチン
JP2012506421A (ja) 2008-10-24 2012-03-15 パナセア バイオテック リミテッド 新規な無細胞百日咳ワクチン組成物およびその製造方法
WO2012093406A2 (en) 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MJA，2006年，Vol. 184, No. 4，pp. 170-175

Also Published As

Publication number Publication date
MX2020000441A (es) 2020-08-17
KR102657910B1 (ko) 2024-04-18
US20200206331A1 (en) 2020-07-02
UA128204C2 (uk) 2024-05-08
JOP20180069A1 (ar) 2019-01-18
SG11202000224SA (en) 2020-02-27
PH12020500133A1 (en) 2021-02-08
UY37811A (es) 2019-01-02
PE20201443A1 (es) 2020-12-10
ZA202000889B (en) 2021-06-30
KR20200042470A (ko) 2020-04-23
TWI786153B (zh) 2022-12-11
TW201919690A (zh) 2019-06-01
CO2020001765A2 (es) 2020-05-29
JP2020527571A (ja) 2020-09-10
AU2018302767B2 (en) 2025-04-10
US11179453B2 (en) 2021-11-23
CN111032078A (zh) 2020-04-17
JOP20180069B1 (ar) 2022-09-15
GEP20227386B (en) 2022-06-10
EA202090316A1 (ru) 2020-12-08
WO2019016654A1 (en) 2019-01-24
CA3070039A1 (en) 2019-01-24
EP3655024A1 (en) 2020-05-27
BR112020000999A2 (pt) 2020-07-14
AU2018302767A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
JP7404226B2 (ja) 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
KR102822878B1 (ko) 감소된 용량의 불활성화된 폴리오바이러스를 포함하는 조합 백신 조성물 및 그의 제조 방법
JP4233113B2 (ja) 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
JP4954056B2 (ja) 低用量のＨｉｂ結合体との組合せワクチン
JP2010514818A (ja) ワクチン
JP2015531389A (ja) 免疫原性組成物
CN102196817B (zh) 具有全细胞百日咳的联合疫苗
KR102607295B1 (ko) 다가 백신 조성물
EP4327820A1 (en) Liquid sextuple vaccine composition
EA047205B1 (ru) Состав полностью жидкой комбинированной вакцины с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ её получения
EA043311B1 (ru) Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
US11793869B2 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
JP2000511553A (ja) ボルデテラ・ペルツッシスの外膜タンパク質フラグメントを有してなるワクチン組成物
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
OA21991A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231213

R150 Certificate of patent or registration of utility model

Ref document number: 7404226

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150